(Q38195788)

30 August 2017

1 reference

title

Dopamine receptor mapping with PET imaging in Parkinson's disease (English)

1 reference

30 August 2017

1 reference

1

Flavia Niccolini

1 reference

30 August 2017

3

Marios Politis

1 reference

30 August 2017

Paul Su

2

1 reference

30 August 2017

publication date

15 March 2014

1 reference

30 August 2017

1 reference

30 August 2017

volume

261

1 reference

30 August 2017

issue

12

1 reference

30 August 2017

page(s)

2251-2263

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

30 August 2017

1 reference

21 January 2018

Basal ganglia disease

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Motor impairment in PD: relationship to incident dementia and age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Positron emission tomography imaging in neurological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Positron emission tomography provides molecular imaging of biological processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Preparation of 11C-labelled SCH 23390 for the in vivo study of dopamine D-1 receptors using positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

[11C]NNC 112 selectivity for dopamine D1 and serotonin 5-HT(2A) receptors: a PET study in healthy human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

A PET study of D(1)-like dopamine receptor ligand binding during altered endogenous dopamine levels in the primate brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Dopamine D(1) receptor expression in human basal ganglia and changes in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

In vivo studies on striatal dopamine D 1 and D 2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Pre- and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [18F]FDOPA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

In vivo DA D(1) receptor selectivity of NNC 112 and SCH 23390.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Imaging cortical dopamine D1 receptors using [11C]NNC112 and ketanserin blockade of the 5-HT 2A receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

18F-desmethoxyfallypride: a fluorine-18 labeled radiotracer with properties similar to carbon-11 raclopride for PET imaging studies of dopamine D2 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

In vitro affinities of various halogenated benzamide derivatives as potential radioligands for non-invasive quantification of D(2)-like dopamine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

A preliminary PET evaluation of the new dopamine D2 receptor agonist [11C]MNPA in cynomolgus monkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Asymmetrical pre-synaptic and post-synpatic changes in the striatal dopamine projection in dopa naïve parkinsonism. Diagnostic implications of the D2 receptor status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

PET demonstrates different behaviour of striatal dopamine D-1 and D-2 receptors in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

[11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Role of dopaminergic treatment in dopamine receptor down-regulation in advanced Parkinson disease: a positron emission tomographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Dopamine D3 receptor mRNA and binding sites in human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Dopamine receptors labelled by PHNO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

High-affinity states of human brain dopamine D2/3 receptors imaged by the agonist [11C]-(+)-PHNO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: Studies in non-human primates and transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Upregulation of dopamine D2 receptors in dopaminergic drug-naive patients with Parkin gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Kinetic Modeling of [11C]Raclopride: Combined PET-Microdialysis Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Recent advances in atypical parkinsonian disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

The dopamine D2 receptor ligand 18F-desmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

The value of the dopamine D2/3 receptor ligand 18F-desmethoxyfallypride for the differentiation of idiopathic and nonidiopathic parkinsonian syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

[¹⁸F]FDG-PET is superior to [¹²³I]IBZM-SPECT for the differential diagnosis of parkinsonism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: an in vivo 11C-raclopride PET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Extrastriatal dopamine D(2) receptors in Parkinson's disease: a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Raclopride studies of dopamine release: dependence on presynaptic integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Endogenous dopamine release after pharmacological challenges in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients: positron emission tomographic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Cognitive deficits and striato-frontal dopamine release in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Apomorphine-induced changes in synaptic dopamine levels: positron emission tomography evidence for presynaptic inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Factors affecting the clinical outcome after neural transplantation in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Dyskinesia after fetal cell transplantation for parkinsonism: a PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Impulsive choice and response in dopamine agonist-related impulse control behaviors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

The DSM-III-R impulse control disorders not elsewhere classified: clinical characteristics and relationship to other psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Compulsive drug use linked to sensitized ventral striatal dopamine transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Dopaminergic and clinical correlates of pathological gambling in Parkinson's disease: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: a [11C] FLB-457 and PET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Understanding the placebo effect. Part 2: underlying psychological & neurobiological processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

The placebo-reward hypothesis: dopamine and the placebo effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Dopamine release in human ventral striatum and expectation of reward

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Effects of expectation on placebo-induced dopamine release in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Treadmill exercise elevates striatal dopamine D2 receptor binding potential in patients with early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7302-2

Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover

21 January 2018

1 reference

12 December 2020

Production of 3-N-[11C]methylspiperone with high specific activity and high radiochemical purity for PET studies: suppression of its radiolysis

1 reference

12 December 2020

(-)-N-[(11)C]propyl-norapomorphine: a positron-labeled dopamine agonist for PET imaging of D(2) receptors

1 reference

12 December 2020

Striatal D2 dopamine receptor status in Parkinson's disease: an [18F]dopa and [11C]raclopride PET study

1 reference

12 December 2020

Basal ganglia and movement disorders: an update

1 reference

12 December 2020

1 reference

12 December 2020

Physiology and pathophysiology of Parkinson's disease.

1 reference

12 December 2020

The placebo response in Parkinson's disease. Parkinson Study Group

1 reference

12 December 2020

PET studies on dopamine D1 receptors in the human brain with carbon-11-SCH 39166 and carbon-11-NNC 756

1 reference

12 December 2020

Positron emission tomography of brain dopamine D-1 receptors with 11C-SCH 23390 in Parkinson's disease

1 reference

12 December 2020

Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease

1 reference

12 December 2020

Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride

1 reference

12 December 2020

Dyskinesias following neural transplantation in Parkinson's disease

1 reference

12 December 2020

Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone

1 reference

12 December 2020

Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors

1 reference

12 December 2020

10.1007/S00415-014-7302-2

Identifiers

DOI

1 reference

Dimensions Publication ID

30 August 2017

1034266894

0 references

1 reference